Skip to main content
Premium Trial:

Request an Annual Quote

Peter Coggins, Arthur Caputo, Marc Casper, Laura Lauman, Chris van Ingen, Andrew Carr

Bill Linton, chairman and CEO of Promega, has been elected chairman of the Analytical and Life Science Systems Association, a molecular-biology tools industry trade group. Linton succeeds Joe Keegan of Molecular Devices.

Peter Coggins, president of PerkinElmer’s Life and Analytical Sciences unit, was elected vice chairman and chairman-elect of the group, it said last week.

Lukas Braunschweiler, president and CEO of Dionex; Benjamin Bulkley, senior vice president for commercial operations of Invitrogen; Joel McComb, president, Discovery Systems, GE Healthcare; Brian McKernan, CEO of Agencourt Bioscience; and Volker Pfahlert, head of Roche Applied Science, were elected to the organization’s board of directors.

According to the organization, nine directors were reelected, including: Arthur Caputo, president, Waters Division of Waters Corp.; Marc Casper, president, Life & Laboratory Sciences, Thermo Electron; Haseeb Chaudhry, CEO of Alpha Innotech; Jay Flatley, president and CEO of llumina; Lissa Goldenstein, president and CEO of Argonaut Technologies; Laura Lauman, president, proteomics and small molecule division of Applied Biosystems; Riccardo Pigliucci, chairman and CEO, Discovery Partners International; Garry Rogerson, president and CEO, Varia.; and Chris van Ingen, president, Life Science & Chemical Analysis, of Agilent Technologies, the group said.

Andrew Carr, former president of discovery systems for GE Healthcare, is now functioning in an advisory role within the company. Carr was replaced by Joel McComb in August, who joined the company from a position as president and CEO of Innovadyne Technologies. McComb’s previous work experience included a position heading the primary care division of Beckman Coulter.

Mark Pykett will join Boston Life Sciences as executive vice president and chief operating officer, the company said last week. Pykett joins the company from Cytomatrix, where he was president and CEO. Cytomatrix recently merged with CyGenics.

Additionally, Robert Gipson and Marc Lanser resigned from Boston Life Science’s board of directors. Lanser will remain as president and chief science officer of BLS.

Gary Cupit joined Rejuvenon as its new president and CEO, the company said. Previously, Cupit headed search and evalution for global business development and licensing at Novartis. He previously worked at Knoll Pharmaceutical, The Medicines Company, and SmithKline Beecham.

The Woodlands, Texas-based pharmaceutical company said it would consolidate all its operations to New Jersey, where its development team is presently located.

University of Oregon chemistry professor Peter von Hippel, an American Cancer Society Career Research Professor as director of the university’s Institute of Molecular Biology for 11 years, will join the American Philosophical Society. The group is an academic organization founded in 1743 by Benjamin Franklin with members including George Washington, Albert Einstein, Robert Frost, and Linus Pauling.

Holger Reithinger will join German Global Life Science Ventures as principal in the private-equity firm's Munich offices, the company announced last month. Previously, Reithinger was director of 3i healthcare practices, overseeing investments in Europe.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.